ESMO 2016 Congress Officers 2016 ESMO and Congress President Fortunato Ciardiello, Naples, Italy Scientific Committee Chair Andrés Cervantes, Valencia, Spain Educational Chair Jean-Yves Douillard, Lugano, Switzerland Press Officer Solange Peters, Lausanne, Switzerland Local Officer Ulrik N. Lassen, Copenhagen, Denmark Scientific Committee Basic science and translational research Chair: Richard Marais, Manchester, UK Catherine Alix-Panabieres, Montpellier, France Anton Berns, Amsterdam, Netherlands Alberto Bardelli, Candiolo, Italy Carlos Caldas, Cambridge, UK Raffaele Califano, Manchester, UK Robert Gatenby, Tampa, FL, USA Ramaswamy Govindan, St. Louis, MO, USA David Huntsman, Vancouver, BC, Canada Clare Isacke, London, UK Joan Seoane, Barcelona, Spain Sheila Singh, Hamilton, ON, Canada Thomas Tüting, Bonn, Germany Christ<strong>of</strong> von Kalle, Heidelberg, Germany Breast cancer, early stage Chair: Marco Colleoni, Milan, Italy Hatem A. Azim, Jr., Marseille, France Jacques Bernier, Genolier, Switzerland Herve Bonnefoi, Bordeaux, France Karen Gelmon, Vancouver, BC, Canada Nadia Harbeck, Munich, Germany Guy Jerusalem, Liege, Belgium Sybille Loibl, Neu-Isenburg, Germany Aleix Prat, Barcelona, Spain Isabel T. Rubio, Barcelona, Spain Elżbieta Senkus-Konefka, Gdańsk, Poland Andrew Tutt, London, UK Giuseppe Viale, Milan, Italy Breast cancer, metastatic Chair: Robert E. Coleman, Sheffield, UK Fabrice André, Villejuif, France Fatima Cardoso, Lisbon, Portugal Pier Franco Conte, Padua, Italy Javier Cortes, Barcelona, Spain Luis Costa, Lisbon, Portugal Roger Gomis, Barcelona, Spain Nadia Harbeck, Munich, Germany Per Karlsson, Gothenburg, Sweden Sherene Loi, Melbourne, Australia Peter Schmid, London, UK David Warr, Toronto, ON, Canada Developmental therapeutics Chair: Jordi Rodón, Barcelona, Spain Udai Banerji, Sutton, UK Mark Basik, Montreal, QC, Canada Irene Braña, Barcelona, Spain Mario Campone, Saint Herblain, France Bryan Hennessy, Dublin, Ireland Chia-Chi Lin, Taipei, Taiwan Christophe Massard, Villejuif, France Paolo Nuciforo, Barcelona, Spain Christian Rolfo, Edegem, Belgium Jan Schellens, Amsterdam, Netherlands Christopher Twelves, Leeds, UK CNS tumours Chair: Alba Brandes, Bologna, Italy Carmen Balaña, Barcelona, Spain Deborah Blumenthal, Tel Aviv, Israel Michael Brada, Bebington, UK Roger Henriksson, Stockholm, Sweden Simone Niclou, Luxembourg Guido Reifenberger, Dusseldorf, Germany Marc Sanson, Paris, France Colin Watts, Cambridge, UK Michael Weller, Zurich, Switzerland Patrick Wen, Boston, MA, USA Gastrointestinal tumours, colorectal Chair: Julien Taieb, Paris, France Richard Adams, Cardiff, UK Dirk Arnold, Lisbon, Portugal Daniela Aust, Dresden, Germany Chiara Cremolini, Pisa, Italy Thomas Gruenberger, Vienna, Austria Volker Heinemann, Munich, Germany Florence Huguet, Paris, France Claus-Henning Koehne, Oldenburg, Germany Fotios Loupakis, Pisa, Italy Ramon Salazar, L’Hospitalet de Llobergat, Spain Sabine Tejpar, Leuven, Belgium Christophe Tournigand, Creteil, France
Gastrointestinal tumours, non-colorectal Chair: Florian Lordick, Leipzig, Germany Fátima Carneiro, Porto, Portugal Ian Chau, Sutton, UK Eduardo Diaz Rubio, Madrid, Spain Michel Ducreux, Villejuif, France Axel Hillmer, Mainz, Germany Yelena Janjigian, New York, NY, USA Christophe Mariette, Lille, France Per Pfeiffer, Odense, Denmark Fernando Rivera, Santander, Spain Arnaud Roth, Geneva, Switzerland Eric Van Cutsem, Leuven, Belgium Marcel Verheij, Amsterdam, Netherlands Genitourinary tumours, non-prostate Chair: Joaquim Bellmunt, Boston, MA, USA Laurence Albiges, Villejuif, France Ferran Algaba, Barcelona, Spain Aris Bamias, Athens, Greece Axel Bex, Amsterdam, Netherlands Bernard Escudier, Villejuif, France Viktor Grünwald, Hannover, Germany Christian Kollmannsberger, Vancouver, BC, Canada Antonio López-Beltran, Lisbon, Portugal Nicholas Mottet, St. Etienne, France Andrea Necchi, Milan, Italy Jack Schalken, Nijmegen, Netherlands Manuela Schmidinger, Vienna, Austria Genitourinary tumours, prostate Chair: Gerhardt Attard, Sutton, UK Himisha Beltran, New York, NY, USA Johann de Bono, London, UK Ronald de Wit, Rotterdam, Netherlands Eleni Efstathiou, Houston, TX, USA Felix Feng, Ann Arbor, MI, USA Silke Gillessen, St. Gallen, Switzerland Axel Heidenreich, Aachen, Germany Yohann Loriot, Villejuif, France David Olmos, Madrid, Spain Stephane Oudard, Paris, France Mathew Sydes, London, UK Scott Tomlins, Ann Arbor, MI, USA Gynaecological cancers Chair: Sandro Pignata, Naples, Italy Carien L. Creutzberg, Leiden, Netherlands Antonio González-Martín, Madrid, Spain Charlie Gourley, Edinburgh, UK Florence Joly, Caen, France Jonathan Ledermann, London, UK Domenica Lorusso, Milan, Italy Mansoor Mirza, Copenhagen, Denmark Andres Poveda, Valencia, Spain Isabelle Ray-Coquard, Lyon, France Cristiana Sessa, Bellinzona, Switzerland Ignace Vergote, Leuven, Belgium Haematological malignancies Chair: Christian Buske, Ulm, Germany Peter Campbell, Hinxton, UK Andrés Ferreri, Milan, Italy Ramon Garcia-Sanz, Salamanca, Spain Paolo Ghia, Milan, Italy Klaus Herfarth, Heidelberg, Germany Peter Johnson, Southampton, UK Marco Ladetto, Alessandria, Italy Steven Le Gouill, Nantes, France Armando Lopez-Guillermo, Barcelona, Spain Gert J. Ossenkoppele, Amsterdam, Netherlands Mariano Provencio, Madrid, Spain Evangelos Terpos, Athens, Greece Immunotherapy <strong>of</strong> cancer Chair: John Haanen, Amsterdam, Netherlands Philipp Beckhove, Heidelberg, Germany Mario Colombo, Milan, Italy Jérôme Galon, Paris, France Ignacio Melero, Pamplona, Spain Paul Nathan, Northwood, UK Ulf Petrausch, Zurich, Switzerland Thomas Powles, London, UK Suzy Scholl, Paris, France Inge Marie Svane, Herlev, Denmark Sjoerd van der Burg, Leiden, Netherlands Laurence Zitvogel, Villejuif, France Head and neck cancer Chair: Amanda Psyrri, Athens, Greece Ana Castro, Porto, Portugal Sandrine Faivre, Clichy, France Vincent Gregoire, Brussels, Belgium Nikolaos Kavantzas, Athens, Greece Lisa Licitra, Milan, Italy Jean-Pascal Machiels, Brussels, Belgium Marco Merlano, Cuneo, Italy Ricard Mesía, L’Hospitalet de Llobregat, Spain Piero Nicolai, Brescia, Italy Christos Perisanidis, Vienna, Austria Massimo Tommasino, Lyon, France Melanoma and other skin tumours Chair: Olivier Michielin, Lausanne, Switzerland Paolo Ascierto, Naples, Italy Boris C. Bastian, San Francisco, CA, USA Reinhard Dummer, Zurich, Switzerland Jean-Jacques Grob, Marseille, France Axel Hauschild, Kiel, Germany Christoph Hoeller, Vienna, Austria Paul Lorigan, Manchester, UK Josep Malvehy, Barcelona, Spain Caroline Robert, Villejuif, France Benoît Van den Eynde, Brussels, Belgium Jeffrey Weber, New York, NY, USA
- Page 1 and 2: Annals of Oncology Official Journal
- Page 3 and 4: Annals of Oncology Official Journal
- Page 5: The European Society for Medical On
- Page 10 and 11: Annals of Oncology 27 (Supplement 6
- Page 12 and 13: Annals of Oncology Methods: H1975-A
- Page 14 and 15: Annals of Oncology membrane recepto
- Page 16 and 17: Annals of Oncology of RT, and cox r
- Page 18 and 19: Annals of Oncology (NCT01862081) in
- Page 20 and 21: Annals of Oncology 39P IL-6 induces
- Page 22 and 23: Annals of Oncology Conclusions: Thi
- Page 24 and 25: Annals of Oncology 27 (Supplement 6
- Page 26 and 27: Annals of Oncology Conclusions: RAS
- Page 28 and 29: Annals of Oncology acquired resista
- Page 30 and 31: Annals of Oncology circulating tumo
- Page 32 and 33: Annals of Oncology Legal entity res
- Page 34 and 35: Annals of Oncology abstracts associ
- Page 36 and 37: Annals of Oncology abstracts 89P Ta
- Page 38 and 39: Annals of Oncology abstracts cetuxi
- Page 40 and 41: Annals of Oncology genes in breast
- Page 42 and 43: Annals of Oncology These results in
- Page 44 and 45: Annals of Oncology Results: It was
- Page 46 and 47: Annals of Oncology 124P Tandem repe
- Page 48 and 49: Annals of Oncology amplification of
- Page 50 and 51: Annals of Oncology 138P Improved ef
- Page 52 and 53: Annals of Oncology 27 (Supplement 6
- Page 54 and 55: Annals of Oncology abstracts Conclu
- Page 56 and 57:
Annals of Oncology abstracts Legal
- Page 58 and 59:
Annals of Oncology abstracts Fear o
- Page 60 and 61:
Annals of Oncology and OS (p = 0.24
- Page 62 and 63:
Annals of Oncology more so for pati
- Page 64 and 65:
Annals of Oncology Methods: We exam
- Page 66 and 67:
Annals of Oncology abstracts expres
- Page 68 and 69:
Annals of Oncology abstracts calcul
- Page 70 and 71:
Annals of Oncology Funding: Hong Ko
- Page 72 and 73:
Annals of Oncology abstracts in ran
- Page 74 and 75:
Annals of Oncology deleterious effe
- Page 76 and 77:
Annals of Oncology Funding: Clovis
- Page 78 and 79:
Annals of Oncology 224PD Efficacy a
- Page 80 and 81:
Annals of Oncology abstracts ERBB p
- Page 82 and 83:
Annals of Oncology Methods: In this
- Page 84 and 85:
Annals of Oncology Methods: To eval
- Page 86 and 87:
Annals of Oncology 247P Safety and
- Page 88 and 89:
Annals of Oncology particular patie
- Page 90 and 91:
Annals of Oncology abstracts 260P I
- Page 92 and 93:
Annals of Oncology 266P Is the over
- Page 94 and 95:
Annals of Oncology 273P A randomize
- Page 96 and 97:
Annals of Oncology 277P Phase 1b/2
- Page 98 and 99:
Annals of Oncology abstracts lines
- Page 100 and 101:
Annals of Oncology abstracts receiv
- Page 102 and 103:
Annals of Oncology significant bene
- Page 104 and 105:
Annals of Oncology Funding: This re
- Page 106 and 107:
Annals of Oncology complications co
- Page 108 and 109:
Annals of Oncology Trial design: SA
- Page 110 and 111:
Annals of Oncology Legal entity res
- Page 112 and 113:
Annals of Oncology 27 (Supplement 6
- Page 114 and 115:
Annals of Oncology Conclusions: Thi
- Page 116 and 117:
Annals of Oncology Legal entity res
- Page 118 and 119:
Annals of Oncology abstracts consis
- Page 120 and 121:
Annals of Oncology 349P Anaplastic
- Page 122 and 123:
Annals of Oncology the MGMT promote
- Page 124 and 125:
Annals of Oncology 359O First-in-hu
- Page 126 and 127:
Annals of Oncology Funding: Baxalta
- Page 128 and 129:
Annals of Oncology 371P First-in-hu
- Page 130 and 131:
Annals of Oncology abstracts Table:
- Page 132 and 133:
Annals of Oncology Clinical trial i
- Page 134 and 135:
Annals of Oncology Results: As of M
- Page 136 and 137:
Annals of Oncology abstracts Table:
- Page 138 and 139:
Annals of Oncology abstracts 396P R
- Page 140 and 141:
Annals of Oncology Legal entity res
- Page 142 and 143:
Annals of Oncology 408TiP CamBMT1:
- Page 144 and 145:
Annals of Oncology 414TiP Agnostos
- Page 146 and 147:
Annals of Oncology abstracts 418O P
- Page 148 and 149:
Annals of Oncology Disclosure: M. K
- Page 150 and 151:
Annals of Oncology abstracts damagi
- Page 152 and 153:
Annals of Oncology compared with th
- Page 154 and 155:
Annals of Oncology research funding
- Page 156 and 157:
Annals of Oncology abstracts 446P C
- Page 158 and 159:
Annals of Oncology 27 (Supplement 6
- Page 160 and 161:
Annals of Oncology abstracts 458O F
- Page 162 and 163:
Annals of Oncology abstracts 461O A
- Page 164 and 165:
Annals of Oncology TAS-102 group (4
- Page 166 and 167:
Annals of Oncology 469PD Phase III
- Page 168 and 169:
Annals of Oncology Conclusions: REG
- Page 170 and 171:
Annals of Oncology (MTD) and assess
- Page 172 and 173:
Annals of Oncology we evaluate the
- Page 174 and 175:
Annals of Oncology 491P Impact of s
- Page 176 and 177:
Annals of Oncology abstracts 497P P
- Page 178 and 179:
Annals of Oncology 502P Pharmacolog
- Page 180 and 181:
Annals of Oncology ClinStat GmbH (e
- Page 182 and 183:
Annals of Oncology Romania, South A
- Page 184 and 185:
Annals of Oncology GlaxoSmithKline
- Page 186 and 187:
Annals of Oncology abstracts discor
- Page 188 and 189:
Annals of Oncology 50% of patients
- Page 190 and 191:
Annals of Oncology Conclusions: The
- Page 192 and 193:
Annals of Oncology 540P Prospective
- Page 194 and 195:
Annals of Oncology abstracts were u
- Page 196 and 197:
Annals of Oncology abstracts is 81
- Page 198 and 199:
Annals of Oncology Oncology, Inc. P
- Page 200 and 201:
Annals of Oncology abstracts 562P G
- Page 202 and 203:
Annals of Oncology Funding: Novo No
- Page 204 and 205:
Annals of Oncology 574P Prognostic
- Page 206 and 207:
Annals of Oncology abstracts aim of
- Page 208 and 209:
Annals of Oncology and UM than in N
- Page 210 and 211:
Annals of Oncology Methods: TLC bef
- Page 212 and 213:
Annals of Oncology 598TiP APOLLON s
- Page 214 and 215:
Annals of Oncology 604TiP PRODIGE 2
- Page 216 and 217:
Annals of Oncology 27 (Supplement 6
- Page 218 and 219:
Annals of Oncology 614O Final resul
- Page 220 and 221:
Annals of Oncology p = 0.05) pts; i
- Page 222 and 223:
Annals of Oncology the presentation
- Page 224 and 225:
Annals of Oncology 630P Clinical si
- Page 226 and 227:
Annals of Oncology 636P Safety and
- Page 228 and 229:
Annals of Oncology Topo1 (rho = 0.3
- Page 230 and 231:
Annals of Oncology abstracts hypoth
- Page 232 and 233:
Annals of Oncology abstracts surviv
- Page 234 and 235:
Annals of Oncology patients were di
- Page 236 and 237:
Annals of Oncology impact of primar
- Page 238 and 239:
Annals of Oncology 677P Phase 1b st
- Page 240 and 241:
Annals of Oncology abstracts Table:
- Page 242 and 243:
Annals of Oncology months, HR 0.785
- Page 244 and 245:
Annals of Oncology abstracts P = 0.
- Page 246 and 247:
Annals of Oncology evaluate the inc
- Page 248 and 249:
Annals of Oncology Table: 705P Firs
- Page 250 and 251:
Annals of Oncology date of the last
- Page 252 and 253:
Annals of Oncology 27 (Supplement 6
- Page 254 and 255:
Annals of Oncology 721PD FIRSTANA:
- Page 256 and 257:
Annals of Oncology 95% CI, 20%-61%)
- Page 258 and 259:
Annals of Oncology polymerization.
- Page 260 and 261:
Annals of Oncology pantoprazole can
- Page 262 and 263:
Annals of Oncology Conclusions: Our
- Page 264 and 265:
Annals of Oncology abstracts First
- Page 266 and 267:
Annals of Oncology Table: 750P Conc
- Page 268 and 269:
Annals of Oncology grade IV diarrhe
- Page 270 and 271:
Annals of Oncology disease location
- Page 272 and 273:
Annals of Oncology castration-resis
- Page 274 and 275:
Annals of Oncology consulting fees
- Page 276 and 277:
Annals of Oncology abstracts 775PD
- Page 278 and 279:
Annals of Oncology abstracts Method
- Page 280 and 281:
Annals of Oncology Table: 783P Medi
- Page 282 and 283:
Annals of Oncology Results: As of 4
- Page 284 and 285:
Annals of Oncology evaluate the imp
- Page 286 and 287:
Annals of Oncology 799P Adherence t
- Page 288 and 289:
Annals of Oncology Methods: Heavily
- Page 290 and 291:
Annals of Oncology At d 42 and 90,
- Page 292 and 293:
Annals of Oncology Lilly. M. Schmid
- Page 294 and 295:
Annals of Oncology outcomes. 7 AEs
- Page 296 and 297:
Annals of Oncology escalation and r
- Page 298 and 299:
Annals of Oncology Funding: Spanish
- Page 300 and 301:
Annals of Oncology Legal entity res
- Page 302 and 303:
Annals of Oncology Clinical trial i
- Page 304 and 305:
Annals of Oncology Trial design: Ph
- Page 306 and 307:
Annals of Oncology abstracts 858PD
- Page 308 and 309:
Annals of Oncology 862P Hormonal th
- Page 310 and 311:
Annals of Oncology Parameter Table:
- Page 312 and 313:
Annals of Oncology statistical sign
- Page 314 and 315:
Annals of Oncology Methods: In tota
- Page 316 and 317:
Annals of Oncology abstracts 887P S
- Page 318 and 319:
Annals of Oncology abstracts This d
- Page 320 and 321:
Annals of Oncology primers targetin
- Page 322 and 323:
Annals of Oncology 27 (Supplement 6
- Page 324 and 325:
Annals of Oncology months (39,75 in
- Page 326 and 327:
Annals of Oncology 918P A pooled da
- Page 328 and 329:
Annals of Oncology Legal entity res
- Page 330 and 331:
Annals of Oncology 931P Final resul
- Page 332 and 333:
Annals of Oncology abstracts variab
- Page 334 and 335:
Annals of Oncology 943TiP ZUMA-1: A
- Page 336 and 337:
Annals of Oncology Trial design: El
- Page 338 and 339:
Annals of Oncology abstracts 954O C
- Page 340 and 341:
Annals of Oncology abstracts of a f
- Page 342 and 343:
Annals of Oncology abstracts accord
- Page 344 and 345:
Annals of Oncology changing) data w
- Page 346 and 347:
Annals of Oncology 973P The role of
- Page 348 and 349:
Annals of Oncology based on tumor r
- Page 350 and 351:
Annals of Oncology phase II trial t
- Page 352 and 353:
Annals of Oncology statistical anal
- Page 354 and 355:
Annals of Oncology comparing standa
- Page 356 and 357:
Annals of Oncology 1006P Expression
- Page 358 and 359:
Annals of Oncology event-free survi
- Page 360 and 361:
Annals of Oncology 27 (Supplement 6
- Page 362 and 363:
Annals of Oncology Table: 1027P 1st
- Page 364 and 365:
Annals of Oncology abstracts of con
- Page 366 and 367:
Annals of Oncology abstracts Conclu
- Page 368 and 369:
Annals of Oncology 27 (Supplement 6
- Page 370 and 371:
Annals of Oncology Conclusions: M 1
- Page 372 and 373:
Annals of Oncology Disclosure: W. G
- Page 374 and 375:
Annals of Oncology abstracts Method
- Page 376 and 377:
Annals of Oncology 1068P Adenosine
- Page 378 and 379:
Annals of Oncology myeloid-derived
- Page 380 and 381:
Annals of Oncology tolerance and th
- Page 382 and 383:
Annals of Oncology abstracts Table:
- Page 384 and 385:
Annals of Oncology Methods: Medical
- Page 386 and 387:
Annals of Oncology 1100TiP An open-
- Page 388 and 389:
Annals of Oncology 27 (Supplement 6
- Page 390 and 391:
Annals of Oncology arm 1 until no i
- Page 392 and 393:
Annals of Oncology >75 than those
- Page 394 and 395:
Annals of Oncology Advisory role: B
- Page 396 and 397:
Annals of Oncology Funding: Bristol
- Page 398 and 399:
Annals of Oncology 1129P Pretreatme
- Page 400 and 401:
Annals of Oncology 1135P COMBI-rech
- Page 402 and 403:
Annals of Oncology for Adrian Goran
- Page 404 and 405:
Annals of Oncology advisory role: B
- Page 406 and 407:
Annals of Oncology abstracts 1148P
- Page 408 and 409:
Annals of Oncology 1154P Evaluation
- Page 410 and 411:
Annals of Oncology 27 (Supplement 6
- Page 412 and 413:
Annals of Oncology enrichment strat
- Page 414 and 415:
Annals of Oncology biomarkers to be
- Page 416 and 417:
Annals of Oncology 27 (Supplement 6
- Page 418 and 419:
Annals of Oncology demonstrate the
- Page 420 and 421:
Annals of Oncology 27 (Supplement 6
- Page 422 and 423:
Annals of Oncology 1192P Recurrence
- Page 424 and 425:
Annals of Oncology abstracts surger
- Page 426 and 427:
Annals of Oncology abstracts 1208O
- Page 428 and 429:
Annals of Oncology abstracts 1206PD
- Page 430 and 431:
Annals of Oncology 1211PD Cost-effe
- Page 432 and 433:
Annals of Oncology abstracts Table:
- Page 434 and 435:
Annals of Oncology Disclosure: M. N
- Page 436 and 437:
Annals of Oncology Legal entity res
- Page 438 and 439:
Annals of Oncology 1229P First-line
- Page 440 and 441:
Annals of Oncology abstracts intole
- Page 442 and 443:
Annals of Oncology for these servic
- Page 444 and 445:
Annals of Oncology Methods: Eligibl
- Page 446 and 447:
Annals of Oncology abstracts Method
- Page 448 and 449:
Annals of Oncology 1257P Tepotinib
- Page 450 and 451:
Annals of Oncology abstracts associ
- Page 452 and 453:
Annals of Oncology these patients (
- Page 454 and 455:
Annals of Oncology abstracts 1274P
- Page 456 and 457:
Annals of Oncology 1279P nab-paclit
- Page 458 and 459:
Annals of Oncology 1285TiP IFCT-100
- Page 460 and 461:
Annals of Oncology is not yet confi
- Page 462 and 463:
Annals of Oncology outside the subm
- Page 464 and 465:
Annals of Oncology 27 (Supplement 6
- Page 466 and 467:
Annals of Oncology Methods: Registe
- Page 468 and 469:
Annals of Oncology measured were ha
- Page 470 and 471:
Annals of Oncology Polypharmacy ass
- Page 472 and 473:
Annals of Oncology 1327P Opinion on
- Page 474 and 475:
Annals of Oncology readily availabl
- Page 476 and 477:
Annals of Oncology Conclusions: The
- Page 478 and 479:
Annals of Oncology 27 (Supplement 6
- Page 480 and 481:
Annals of Oncology abstracts 1355P
- Page 482 and 483:
Annals of Oncology 1361P Effect of
- Page 484 and 485:
Annals of Oncology Methods: VICAN5
- Page 486 and 487:
Annals of Oncology 1375P Acute diag
- Page 488 and 489:
Annals of Oncology (OR = 0.31; 95%
- Page 490 and 491:
Annals of Oncology effectively and
- Page 492 and 493:
Annals of Oncology 27 (Supplement 6
- Page 494 and 495:
Annals of Oncology 1400PD Anti-PD1
- Page 496 and 497:
Annals of Oncology Conclusions: Hig
- Page 498 and 499:
Annals of Oncology abstracts Disclo
- Page 500 and 501:
Annals of Oncology A. Le Cesne: Hon
- Page 502 and 503:
Annals of Oncology 27 (Supplement 6
- Page 504 and 505:
Annals of Oncology first-in-class f
- Page 506 and 507:
Annals of Oncology 27 (Supplement 6
- Page 508 and 509:
Annals of Oncology abstracts Method
- Page 510 and 511:
Annals of Oncology Legal entity res
- Page 512 and 513:
Annals of Oncology abstracts 1449P
- Page 514 and 515:
Annals of Oncology leukopenia and r
- Page 516 and 517:
Annals of Oncology abstracts for Ad
- Page 518 and 519:
Annals of Oncology time points afte
- Page 520 and 521:
Annals of Oncology abstracts 1473P
- Page 522 and 523:
Annals of Oncology explored predict
- Page 524 and 525:
Annals of Oncology oncologists towa
- Page 526 and 527:
Annals of Oncology 1492P Prevention
- Page 528 and 529:
Annals of Oncology 1499P Evaluation
- Page 530 and 531:
Annals of Oncology changes in blood
- Page 532 and 533:
Annals of Oncology 1510PD Pathologi
- Page 534 and 535:
Annals of Oncology histology epithe
- Page 536 and 537:
Annals of Oncology and T790M. In ad
- Page 538 and 539:
Annals of Oncology ivermectin (dual
- Page 540 and 541:
Annals of Oncology Results: Express
- Page 542 and 543:
Annals of Oncology abstracts of tum
- Page 544 and 545:
Annals of Oncology Disclosure: M. W
- Page 546 and 547:
Annals of Oncology Conclusions: Ove
- Page 548 and 549:
Annals of Oncology patient’s/tumo
- Page 550 and 551:
Annals of Oncology tested. These ma
- Page 552 and 553:
Annals of Oncology Table: 1575P 5FU
- Page 554 and 555:
Annals of Oncology 27 (Supplement 6
- Page 556 and 557:
Annals of Oncology + and triple neg
- Page 558 and 559:
Annals of Oncology abstracts using
- Page 560 and 561:
Annals of Oncology examined by tran
- Page 562 and 563:
Annals Of Oncology drug index Clopi
- Page 564 and 565:
Annals Of Oncology drug index 1287T
- Page 566 and 567:
Annals Of Oncology translational re
- Page 568 and 569:
Annals Of Oncology translational re
- Page 570:
Annals Of Oncology translational re